The Truth About the Drug Companies:How They Deceive Us and What to Do About It

Vatic Note:  As most who read here regularly know, we have covered volumes about psychiatry  scam, using psychotropic drugs riddled with chemicals that can turn a child violent against himself or others, and also have serious sideaffects such as severe headaches and seizures which can cause brain damage to a child, much less to an adult.  This is because of the profits and greed that pervades the industry.  Well, much to my surprise, when you check out the boards of directors of these companies, guess who sits on the boards reflecting ownership in these companies???   You guessed it, the Zionist banker vampire squids.  Research it yourself and see how pervasive they have infiltrated these companies and thus profits over peoples safety now is the redirection of purpose.  This is a good article encapsulating the bigger picture for sure.  Courageous woman.  I call this the "cattleizing" of our children to make them into unthinking robots who will accept slavery as a way of life.  Its also how to keep the profits up for the illegal drugs once the children are taken off the legal ones when they turn 18. And we all know now who runs the illegal drugs and money laundering.   A bit of social engineering here I would say.  The dumbing down of America.  Did you know that a person dies from legal drugs once every 19 minutes?  Thats millions of deaths. MORE THAN FOR ILLEGAL DRUGS, so what should really be banned?   Where are those "mad mothers" when you really need them,  when it comes to drug companies???  The Truth About the Drug Companies: How They Deceive Us and What to Do About It www.wanttoknow.info/healthcoverup by Want to Know editors                                                                                               In this book, her most recent, Marcia Angell explores pharmaceutical research, deplores the rapidly expanding involvement (and distortion of truth) of Big Pharma, and implores us all (physicians, patients, politicians) to do something about it. (VN:  Its listed on Amazon.com for your further investigation)The dust-jacket blurb asserts that Angell, "during her two decades at The New England Journal of Medicine had a front-row seat on the growing corruption of the pharmaceutical industry." Since leaving the Journal, she's gone behind the curtains of Big Pharma, Big University, and Big Faculty. Drawing on her own work and on her thoughtful analysis of research, company financial statements, and investigative reports into drug development and marketing, Angell writes with the unambiguous and unyielding style that Journal readers came to expect and trust. The current slide toward the commercialization and corruption of clinical research coincided with the election of President Ronald Reagan in 1980 and the passage of the Bayh-Dole Act, a new set of laws that permitted and encouraged universities and small businesses to patent discoveries from research sponsored by the National Institutes of Health (NIH). Research paid for by the public to serve the public instantly became a private, and salable good – one that is producing drug sales of more than $200 billion a year. Commercialization had both specific and broad effects. Readers of this journal and others are familiar with investigations into the control that research sponsors at pharmaceutical companies exert on the design and analysis of clinical trials (including the distortion of primary outcome measures in trials) and the issue of reporting, nonreporting, and biased reporting of results. Angell reminds us of the increasingly cozy relationships between big industry and the faculties of universities.Not only are narcissistic donors renaming the medical schools; they are buying access to the best minds of their faculties. Angell's examples of the large consulting fees paid by industry to individual faculty members and to NIH scientists and directors are astounding. The broader effects are felt in the commercialization of universities, medical faculties, and our profession. In 2000, in a letter written in response to Angell's Journal editorial, "Is Academic Medicine for Sale?" a reader supplied the answer: "No. The current owner is very happy with it." The increasing intrusion of industry into medical education and the almost complete domination of continuing medical education (especially regarding drugs) by the marketing departments of large pharmaceutical companies are a scandal. The same companies also spend heavily to lobby governments. According to Angell, Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry's U.S. trade association has "the largest lobby in Washington," which in 2002 employed 675 lobbyists (including 26 former members of Congress) at a cost of more than $91 million. The result has been above-average growth in corporate profits during both Republican and Democratic administrations. The most recent and perplexing lobbying effort caused Congress explicitly to prohibit Medicare from using its huge purchasing power to get lower prices for drugs, thus opening up a dollar pipeline, in the form of higher drug prices, directly from taxpayers to corporate coffers. These changes, along with the cave-in by the Food and Drug Administration (FDA) in 1997 that permitted direct-to-consumer advertising to bypass mention in their ads of all but the most serious side effects, have further augmented profits. The overall effect has been a corruption not only of science but also of the dissemination of science. Angell documents that, contrary to what they claim, large pharmaceutical companies have "paltry output" in innovative research. In fact, as permitted by Bayh-Dole, pharmaceutical companies buy discoveries coming out of the basic-science enterprises, including universities and publicly funded granting agencies. The real costs of research on drugs by pharmaceutical companies are much less than the oft-quoted $800 million or so per new drug brought to market. Most of their research is on me-too drugs – unoriginal, tax-deductible (and thus paid for in lost taxes by the public), and mostly unnecessary. The Big Pharma companies are, in essence, manufacturing and marketing companies. Angell's concluding chapter, the least convincing in an otherwise fascinating and penetrating book, contains the solutions, all of them predictable: control me-too drugs, re-empower the FDA, oversee Big Pharma's clinical research, curb patent length and abuse, keep Big Pharma out of medical education, make company financial statements transparent (so we can tell what the costs of research really are, as distinct from marketing), and impose price controls or guidelines. Granted, the problems are so prevalent and the corporate tentacles so entwined with our way of being that it is hard to see what else to recommend. But perhaps Angell is right. We must change the way we manage research and the development and distribution of new drugs. Not only are health and health care at risk, but so are the research enterprise and the reputations of universities and governments. The integrity of scientific research is too important to be left to the invisible hand of the marketplace. Book review written by John Hoey, M.D., former editor-in-chief of the Canadian Medical Association Journal To purchase The Truth About Drug Companies from amazon.com, click here  The quote at the top is from Dr. Angell's summary of her own book in the New York Review of Books. For a riveting 10-page summary of Dr. Angell's book, click here For more reliable, verifiable health cover-up information click here

Overwhelmed by this material? Click here

---

The article is reproduced in accordance with Section 107 of title 17 of the Copyright Law of the United States relating to fair-use and is for the purposes of criticism, comment, news reporting, teaching, scholarship, and research.